The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Gemcitabine (G) fixed-dose-rate infusion (FDR) plus erlotinib (E) in patients with advanced pancreatic cancer (APC).
Alberto Munoz Llarena
Disclosure not yet available
Joan Manel Mane
Disclosure not yet available
Guillermo Lopez-Vivanco
Disclosure not yet available
Abigail Ruiz de Lobera
Disclosure not yet available
Aintzane Sancho
Disclosure not yet available
Eluska Iruarrizaga
Disclosure not yet available
Mikel Arruti
Disclosure not yet available
Ines Marrodan
Disclosure not yet available
Natalia Fuente
Disclosure not yet available
David Ballesteros
Disclosure not yet available